Ikonisys S.A.

Equities

ALIKO

FR00140048X2

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 03:00:24 2024-07-12 am EDT			5-day change	1st Jan Change
1.47 ^EUR	+0.68%		+5.00%	-5.77%

Jul. 10	Ikonisys Unit Secures Four-year Supply Deals in Italy	MT
Jul. 02	Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

July 02, 2024 at 02:30 am EDT

Ikonisys S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.448557 million compared to EUR 0.616866 million a year ago. Net loss was EUR 2.27 million compared to EUR 2.45 million a year ago.

Latest news about Ikonisys S.A.

Ikonisys Unit Secures Four-year Supply Deals in Italy	Jul. 10	MT
Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Jul. 02	CI
Ulisse Biomed and Ikonisys together to innovate oncology diagnostics	Jun. 13	AN
Ikonisys, Ulisse Biomed to Collaborate on New Cancer Diagnostic Technologies	Jun. 12	MT
Ikonisys S.A. announced that it has received ?1.150001 million in funding	Jun. 02	CI
Ikonisys S.A. Announces Postponement of the Publication of its 2023 Annual Financial Report	May. 24	CI
HHospitex Signs Distribution Partnership with Diagen LLC	May. 21	CI
Ikonisys Announces the Postponement of the Publication of Its Annual Financial Report	Apr. 30	CI
Ikonisys Says Hospitex Wins Italian Tender for Diagnostic Systems	Feb. 19	MT
Ikonisys: production record for Hospitex	Jan. 02	CF
Ikonisys: private placement for one million euros	Dec. 29	CF
Diagnostics Group Ikonisys Raises EUR1 Million Via Share Issue	Dec. 29	MT
Ikonisys S.A. Announces the Completion of ?1 Million Private Placement to Speed Up Growth Following Recent Pivotal Deals	Dec. 28	CI
Hospitex International, Pathologists Beyond Borders Association Team Up to Develop Early Cancer Diagnosis Systems	Dec. 15	MT
Ikonisys Strikes EUR5 Million Deal to Buy Italian Peer Hospitex International	Nov. 30	MT
Ikonisys S.A. entered into an agreement to acquire Hospitex International S.R.L. for ?3.5 million.	Nov. 29	CI
Ikonisys SA and Biocare Medical Forge Alliance	23-10-31	CI
Ikonisys S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-30	CI
Ikonisys US Subsidiary Completes ISO Recertification	23-10-17	MT
Ikonisys Completes Study for Immuno-Oncology Platform to Detect Extremely Rare Cells	23-10-10	MT
Ikonisys Raises New Financing Via Columbia Threadneedle	23-08-04	MT
Ikonisys SA Announces Completion of New Financing via the Issuance of a EUR 0.5 Million Private Note	23-08-03	CI
Ikonisys S.A. announced that it has received ?0.5 million in funding	23-08-02	CI
Ikonisys Signs Distribution Deal With Integrated Gulf Biosystems Group	23-07-31	MT
Ikonisys Secures Sale, Installation of Ikoniscope20max in US	23-07-28	MT

Chart Ikonisys S.A.

Duration

Period

More charts

Company Profile

Ikonisys S.A. is specialized in the design, manufacture and marketing of medical diagnostic equipment. The company offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. Net sales break down by source of revenue as follows: - sales of products (65.3%): sales of Ikoniscope instruments and the related software application; - sales of maintenance services (34.7%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-10-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ikonisys S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.47 EUR

Average target price

6.3 EUR

Spread / Average Target

+328.57%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
IKONISYS S.A.	-5.77%	16.91M
BIOMÉRIEUX	-4.72%	12.35B
LANTHEUS HOLDINGS, INC.	+99.06%	8.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.10%	6.6B
DIASORIN S.P.A.	+8.48%	5.88B
AUTOBIO DIAGNOSTICS CO., LTD.	-22.96%	3.52B
ANDON HEALTH CO., LTD.	+6.08%	2.55B
MYRIAD GENETICS, INC.	+38.04%	2.39B
VITROLIFE AB	-7.04%	2.33B
10X GENOMICS, INC.	-68.75%	2.09B

Diagnostic & Testing Substances